Clinical trials
Phase 2 trials in Nigeria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Recruiting | 11 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Chicago | 5 |
| Obafemi Awolowo University Teaching Hospital | 3 |
| Vanderbilt University Medical Center | 3 |
| Bernhard Nocht Institute for Tropical Medicine | 2 |
| Forma Therapeutics, Inc. | 2 |
| Lagos State University | 2 |
| Obafemi Awolowo University | 2 |
| Alex Ekwueme Federal University Teaching Hospital | 1 |
| Arisan Therapeutics, Inc. | 1 |
| Darlington-Peter Chibuzor Ugoji | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 5 |
| Lassa Fever | 4 |
| Anemia, Sickle Cell | 3 |
| Hemorrhagic Fevers, Viral | 3 |
| Acquired Immunodeficiency Syndrome | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Tuberculosis | 2 |
| Tuberculosis, Pulmonary | 2 |
| Albuminuria | 1 |
| Anemia | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.